osimertinib mesylate

Min.Order / FOB Price:Get Latest Price

0 Metric Ton	Negotiable

0 Metric Ton

Negotiable

Product Details
Company Profile

Min.Order :0 Metric Ton
Purity: 98.0%-102.0%

Keywords

osimertinib mesylate 98.0%-102.0% Frontida

Quick Details

Appearance:
Application:First-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations；metastatic EGFR T790M mutation-positive NSCLC in patients whose disease has
PackAge:
ProductionCapacity:|Metric Ton|Day
Storage:
Transportation:

Superiority:

Oxitinib is the third generation irreversible oral EGFR-TKI with central nervous system activity, which can effectively and selectively inhibit EGFR sensitive mutation and EGFR T790M drug-resistant mutation.

View All